<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">35605891</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1873-3476</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>20</Day>
            </PubDate>
          </JournalIssue>
          <Title>International journal of pharmaceutics</Title>
          <ISOAbbreviation>Int J Pharm</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Modulating Insulin Signaling and Trafficking at the Blood-Brain Barrier Endothelium Using Lipid Based Nanoemulsions.</ArticleTitle>
        <Pagination>
          <StartPage>121823</StartPage>
          <MedlinePgn>121823</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijpharm.2022.121823</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0378-5173(22)00378-7</ELocationID>
        <Abstract>
          <AbstractText>The compositionally distinct lipid rafts present in the plasma membrane regulates the restrictive trafficking and signal transduction in the blood-brain barrier (BBB) endothelium. Several metabolic and neurodegenerative diseases are associated with lipid homeostasis disruption within the BBB endothelium. Here, we hypothesized that the delivery of lipid triglyceride based nanoemulsions containing unsaturated fatty acids (UFAs) provides a novel non-pharmacological approach to modulate lipid raft integrity and rectify the aberrant trafficking and signal transduction. The current study has shown that soybean oil nanoemulsions (SNEs) altered the morphology of lipid rafts that are stained by Alex Fluor 647 labelled cholera toxin (AF647-CTX) in polarized hCMEC/D3 cell monolayers. Moreover, western blot and flow cytometry analysis showed that SNEs containing polyunsaturated fatty acids (PUFAs) increased phospo-AKT (p-AKT) expression, a marker for the stimulation of metabolic arm of the insulin signaling, and insulin uptake in human cerebral microvascular endothelial cell (hCMEC/D3) monolayers. However, olive oil nanoemulsions (ONEs) containing monounsaturated fatty acids (MUFAs) had no detectable impact on lipid raft integrity, AKT phosphorylation, or insulin uptake. These findings provided direct evidence that SNEs containing PUFAs can upregulate insulin-pAKT pathway, facilitate insulin trafficking at the BBB, and thereby address cerebrovascular dysfunction in metabolic and neurodegenerative diseases.</AbstractText>
          <CopyrightInformation>Copyright Â© 2022. Published by Elsevier B.V.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Lushan</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutics and (a)Brain Barriers Research Center, University of Minnesota, College of Pharmacy, Minneapolis, Minnesota, 55455, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wiedmann</LastName>
            <ForeName>Timothy S</ForeName>
            <Initials>TS</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutics and (a)Brain Barriers Research Center, University of Minnesota, College of Pharmacy, Minneapolis, Minnesota, 55455, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kandimalla</LastName>
            <ForeName>Karunya K</ForeName>
            <Initials>KK</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutics and (a)Brain Barriers Research Center, University of Minnesota, College of Pharmacy, Minneapolis, Minnesota, 55455, United States. Electronic address: kkandima@umn.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>20</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Int J Pharm</MedlineTA>
        <NlmUniqueID>7804127</NlmUniqueID>
        <ISSNLinking>0378-5173</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Insulin resistance</Keyword>
        <Keyword MajorTopicYN="N">Insulin signaling</Keyword>
        <Keyword MajorTopicYN="N">Insulin trafficking</Keyword>
        <Keyword MajorTopicYN="N">Lipid rafts</Keyword>
        <Keyword MajorTopicYN="N">Nanoemulsions</Keyword>
        <Keyword MajorTopicYN="N">Olive oil</Keyword>
        <Keyword MajorTopicYN="N">Soybean oil</Keyword>
        <Keyword MajorTopicYN="N">Unsaturated fatty acids</Keyword>
      </KeywordList>
      <CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>23</Day>
          <Hour>19</Hour>
          <Minute>27</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35605891</ArticleId>
        <ArticleId IdType="doi">10.1016/j.ijpharm.2022.121823</ArticleId>
        <ArticleId IdType="pii">S0378-5173(22)00378-7</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
